Novel, dose intensive, single-agent cisplatin in the first- line management of advanced stage ovarian cancer
Open Access
- 1 November 1992
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 2 (6) , 301-306
- https://doi.org/10.1046/j.1525-1438.1992.02060301.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989
- Current status of chemotherapy for ovarian carcinomaEuropean Journal of Cancer and Clinical Oncology, 1988
- Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.Journal of Clinical Oncology, 1987
- Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.Journal of Clinical Oncology, 1987
- A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.Journal of Clinical Oncology, 1986
- A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group studyCancer, 1986
- A review of second-look laparotomy for ovarian cancerGynecologic Oncology, 1986
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Second-look laparotomy in ovarian cancerGynecologic Oncology, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958